Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 9,512 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Not applicable Interventional

HIV, Equity, and Addiction Training (HEAT) Program

NCT06370481
View directory record Official record
Conditions
Substance Use Disorders, Hiv, Opioid Use Disorder, Stimulant Use (Diagnosis)
Interventions
Telemedicine, Standard of care
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

NCT03627767
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Scalable, IVR-supported Cancer Prevention Interventions in the Rural Alabama Black Belt

NCT03903874
View directory record Official record
Conditions
Physical Activity
Interventions
Deep south Interactive voice response system supported Active Lifestyle (DIAL)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

NCT04474197
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
VX-864, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 17, 2026, 7:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

NCT02457910
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 17, 2026, 7:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing

NCT01427023
View directory record Official record
Conditions
Trichomonas Vaginalis
Interventions
APTIMA Trichomonas vaginalis (ATV) Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
14 Years and older · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Results available

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

NCT01134731
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
paliperidone, lithium, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

NCT00065312
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
naveglitazar
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 17, 2026, 7:24 AM EDT
Terminated Phase 3 Interventional Results available

Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

NCT01336894
View directory record Official record
Conditions
Lung Cancer
Interventions
therapeutic conventional surgery, iodine I 125, stereotactic body radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 7:24 AM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

NCT00020566
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, busulfan, doxorubicin hydrochloride, etoposide, ifosfamide, melphalan, vincristine sulfate, autologous hematopoietic stem cell transplantation, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Leicester
Other
Eligibility
Up to 49 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00002756
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 1 Year
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
128
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

NCT03395639
View directory record Official record
Conditions
Cardiac Disease
Interventions
Edoxaban, Standard of Care (SOC)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

NCT05032157
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open-label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00085254
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
cilengitide, temozolomide, radiation therapy, laboratory biomarker analysis, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Not applicable Interventional Results available

Detect Fluid Early From Intra-thoracic Impedance Monitoring

NCT00916929
View directory record Official record
Conditions
Heart Failure
Interventions
Impedance Monitoring Feature
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00006102
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
198
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Not applicable Interventional

Providing an Optimized and Empowered Pregnancy for You (POPPY) Aim 3: Randomized Controlled Trial

NCT06510075
View directory record Official record
Conditions
Pregnancy Complications, Maternal Distress, Adverse Birth Outcomes, Infant Conditions
Interventions
Digital Health intervention, Community Health Worker, Digital Health Intervention plus Community Health Worker
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 49 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of ALT-801 in the Treatment of Obesity

NCT05295875
View directory record Official record
Conditions
Obesity/Overweight
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
31
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 17, 2026, 7:24 AM EDT
Completed No phase listed Observational

Longitudinal Study of Vaginal Flora

NCT00340275
View directory record Official record
Conditions
Vaginal Flora
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
15 Years to 44 Years · Female only
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 7:24 AM EDT